Consortium Highlights & Events
Consortium Highlights & Events
Consortium Highlights & Events
February, 2025
January, 2025
We are pleased to share that the University of Pennsylvania (UPenn) is our third participating site which is now active for enrollment
We are pleased to share that the University of Pennsylvania (UPenn) is our third participating site which is now active for enrollment
PETAL goes LIVE on social media! As we ramp up our efforts, the PETAL Consortium is now active on Facebook, LinkedIn, Instagram, and Twitter. Follow us for regular updates, insightful resources, and exciting developments in T-cell lymphoma research. Let’s make science accessible and drive meaningful change together.
PETAL goes LIVE on social media! As we ramp up our efforts, the PETAL Consortium is now active on Facebook, LinkedIn, Instagram, and Twitter. Follow us for regular updates, insightful resources, and exciting developments in T-cell lymphoma research. Let’s make science accessible and drive meaningful change together.
December, 2024
The PETAL team proudly participated in the ASH 2024 conference, showcasing our work through three poster presentations and an oral session. This opportunity highlighted PETAL’s innovative contributions to the field of hematology.
The PETAL team proudly participated in the ASH 2024 conference, showcasing our work through three poster presentations and an oral session. This opportunity highlighted PETAL’s innovative contributions to the field of hematology.
The PETAL Consortium held its second annual Investigators’ Meeting, highlighting significant study progress, sharing operational and regulatory updates, along with celebrating milestones, and outlining strategic goals for the future of the consortium.
The PETAL Consortium held its second annual Investigators’ Meeting, highlighting significant study progress, sharing operational and regulatory updates, along with celebrating milestones, and outlining strategic goals for the future of the consortium.
November, 2024
The BROAD Institute joins PETAL as a genomics collaborator, bringing cutting-edge expertise to the consortium.
The BROAD Institute joins PETAL as a genomics collaborator, bringing cutting-edge expertise to the consortium.
September, 2024
PETAL consortium’s second site Dana Farber Cancer Institute (DFCI) is successfully activated for enrollment
PETAL consortium’s second site Dana Farber Cancer Institute (DFCI) is successfully activated for enrollment
August, 2024
Daiichi Sankyo Inc. and Kyowa Kirin join as the key sponsors to advance the future research at PETAL consortium
Daiichi Sankyo Inc. and Kyowa Kirin join as the key sponsors to advance the future research at PETAL consortium
July, 2024
Acrotech Biopharma joins PETAL, supporting the development of the consortium and personalized treatments for rare lymphomas.
Acrotech Biopharma joins PETAL, supporting the development of the consortium and personalized treatments for rare lymphomas.
June, 2024
May, 2024
Mark Sorial receives an educational grant from SecuraBio to develop novel machine learning models to estimate outcomes for patients with peripheral T-cell lymphoma.
Mark Sorial receives an educational grant from SecuraBio to develop novel machine learning models to estimate outcomes for patients with peripheral T-cell lymphoma.
February, 2024
PETAL Consortium’s first site Massachusetts General Hospital (MGH) is successfully activated for patient enrollment
PETAL Consortium’s first site Massachusetts General Hospital (MGH) is successfully activated for patient enrollment
December, 2023
The first PETAL Investigators meeting was held at ASH 2023 conference discussing the scope of PETAL and future of T-cell Lymphoma research.
The first PETAL Investigators meeting was held at ASH 2023 conference discussing the scope of PETAL and future of T-cell Lymphoma research.
@2024 PETAL Consortium • All rights reserved
@2024 PETAL Consortium • All rights reserved